VC005 Tablets Phase 1 Hepatic Impairment PK Study
ClinicalTrials.gov Studies
Summary
A Phase 1 clinical trial (NCT07551557) registered on ClinicalTrials.gov evaluating the pharmacokinetics and safety of a single 25 mg oral dose of VC005 tablets in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function. The study is single-dose, open-label in design and includes both hepatic impairment and healthy female participants. VC005 is an investigational drug tablet under clinical development.
“This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This document is a clinical trial registry entry for NCT07551557, a Phase 1 pharmacokinetics study of VC005 tablets. The trial will assess a single 25 mg oral dose in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function.
Affected parties include clinical investigators conducting the study, pharmaceutical companies developing VC005, and patients meeting hepatic impairment criteria. The registry entry establishes the study parameters and inclusion/exclusion framework but does not impose compliance obligations on external parties.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function
Phase 1 NCT07551557 Kind: PHASE1 Apr 27, 2026
Abstract
This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with mild and moderate hepatic impairment compared to participants with normal hepatic function.
Conditions: Hepatic Impairment and Healthy Female
Interventions: VC005 Tablets
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.